ADDERALL 12.5
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADDERALL 12.5 (ADDERALL 12.5).
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
| Metabolism | Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine. |
| Excretion | Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is pH-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%. |
| Half-life | The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect. |
| Protein binding | Approximately 15–20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence. |
| Bioavailability | Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release. |
| Onset of Action | Immediate-release formulation: Onset of CNS effects occurs within 30–60 minutes after oral administration. Extended-release (e.g., Adderall XR): Onset at 1–2 hours post-dose. |
| Duration of Action | Immediate-release: Duration of therapeutic effect is 4–6 hours. Extended-release: Duration is 8–12 hours. Clinical note: Duration may be shorter in children and longer in adults; tolerance may reduce apparent duration over time. |
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
| Dosage form | TABLET |
| Renal impairment | GFR 15-29 mL/min: reduce dose to 50% of usual; GFR <15 mL/min: use 50% of usual dose; hemodialysis: not removed, avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use. |
| Pediatric use | Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day. |
| Geriatric use | Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ADDERALL 12.5 (ADDERALL 12.5).
| Breastfeeding | Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain. |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported. |
■ FDA Black Box Warning
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
["Known hypersensitivity to amphetamine products or other sympathomimetic amines","Concomitant use with MAOIs or within 14 days of MAOI therapy","Glaucoma","Hyperthyroidism","Agitated states","History of drug abuse","Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias"]
| Precautions | ["Risk of abuse and dependence","Serious cardiovascular events including sudden death, stroke, and myocardial infarction","Blood pressure and heart rate increases","Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression","Seizures in patients with seizure disorders","Visual disturbances","Growth suppression in children","Peripheral vasculopathy including Raynaud's phenomenon","Serotonin syndrome risk when used with serotonergic drugs"] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain; fetal growth via ultrasound (e.g., serial growth scans) and fetal heart rate monitoring. Assess for signs of preeclampsia and preterm labor. Monitor neonatal adaptation post-delivery. |
| Fertility Effects | Amphetamines may impair fertility in females by disrupting menstrual cycles and ovulation; in males, they may reduce sperm count and motility based on animal studies. Human data limited; advise deferring pregnancy until therapy cessation. |
| Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels. |
| Clinical Pearls | ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules. |
| Patient Advice | Take exactly as prescribed; do not increase dose without consulting your doctor. · Swallow the capsule whole; do not chew, crush, or open it. · Avoid alcohol while taking this medication. · Do not drive or operate machinery until you know how this medication affects you. · Report any chest pain, shortness of breath, or fainting to your doctor immediately. · Store at room temperature away from moisture and heat. |